Your session is about to expire
← Back to Search
Behavioral Intervention
Family-Centered Palliative Care for Children with Rare Diseases (FACE-Rare Trial)
N/A
Waitlist Available
Led By Maureen E Lyon, PhD
Research Sponsored by Children's National Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline anxiety at 3 months post-enrollment
Awards & highlights
Summary
This trialseeks to improve palliative care needs of families caring for children with ultra-rare diseases, by piloting a new assessment and intervention.
Who is the study for?
This trial is for English-speaking caregivers of children with ultra-rare diseases, aged between 1 and less than 18 years old. The child must not be in intensive care, under end-of-life orders, or unable to make decisions about their care.
What is being tested?
The FACE pACP Intervention is being tested to see if it helps family caregivers discuss future medical choices for their children with rare diseases. It's a pilot study using new methods to assess palliative care needs.
What are the potential side effects?
Since this intervention involves discussions and planning rather than medication, traditional physical side effects are not expected; however, emotional or psychological stress may occur.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline spiritual well-being at 3 months post-enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline spiritual well-being at 3 months post-enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Advance Care Document for Children with Rare Diseases
Beck Anxiety Inventory
Days in Palliative Care Prior to Death
+7 moreSecondary study objectives
Brief-Multidimensional Measure of Religion and Spirituality
Family Appraisal of Caregiving Questionnaire for Palliative Care
Other study objectives
Hickman Role Stress Decisional Burden Scale
Quality of Communication Questionnaire
Satisfaction Questionnaire
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: FACE-Rare InterventionExperimental Treatment1 Intervention
FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.
Sessions 1\&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.
Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions.
Group II: Treatment-as-Usual (TAU) ControlActive Control1 Intervention
To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
Find a Location
Who is running the clinical trial?
National Institute of Nursing Research (NINR)NIH
598 Previous Clinical Trials
10,378,114 Total Patients Enrolled
Children's National Research InstituteLead Sponsor
218 Previous Clinical Trials
257,862 Total Patients Enrolled
Respecting ChoicesUNKNOWN
1 Previous Clinical Trials
778 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You do not have an order that says you cannot be resuscitated or allowed to pass away naturally.I am 18 years old or older.You can speak and understand English.You are not experiencing significant delays in your physical, mental, or emotional development.You are the legal guardian and caregiver for a child.I am between 1 and 17 years old.You have a medical condition that is considered rare, as defined in the Human Subjects guidelines.You are not currently in the hospital's intensive care unit.This information is incomplete.I cannot make decisions about my end-of-life care.
Research Study Groups:
This trial has the following groups:- Group 1: FACE-Rare Intervention
- Group 2: Treatment-as-Usual (TAU) Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger